Biogen Inc. financial data

Symbol
BIIB on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
225 Binney Street, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
BIOGEN IDEC INC. (to 3/20/2015), BIOGEN IDEC INC (to 4/25/2007), IDEC PHARMACEUTICALS CORP / DE (to 11/12/2003), IDEC PHARMACEUTICALS CORP / CA (to 2/14/1997)
Latest financial report
10-Q - Q3 2024 - Oct 30, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 181 % -31.6%
Quick Ratio 66 % +37.8%
Debt-to-equity 82.1 % -17.1%
Return On Equity 10.4 % -0.38%
Return On Assets 5.95 % +4.38%
Operating Margin 22.9 % -22.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 146M shares +0.57%
Common Stock, Shares, Outstanding 145M shares +0.63%
Entity Public Float 41.2B USD +40.1%
Common Stock, Value, Issued 100K USD 0%
Weighted Average Number of Shares Outstanding, Basic 146M shares +0.62%
Weighted Average Number of Shares Outstanding, Diluted 146M shares +0.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 9.61B USD -3.86%
Costs and Expenses 7.7B USD -8.15%
Operating Income (Loss) 2.48B USD -33.1%
Nonoperating Income (Expense) -852M USD -867%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 451M USD
Income Tax Expense (Benefit) 292M USD +98.6%
Net Income (Loss) Attributable to Parent 1.62B USD +10.5%
Earnings Per Share, Basic 11.1 USD/shares +9.9%
Earnings Per Share, Diluted 11.1 USD/shares +10.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Accounts Receivable, after Allowance for Credit Loss, Current 1.66B USD -2.4%
Inventory, Net 2.47B USD -17.2%
Other Assets, Current 674M USD -30.8%
Assets, Current 6.83B USD -19.2%
Deferred Income Tax Assets, Net 969M USD -9.45%
Property, Plant and Equipment, Net 3.21B USD -2.75%
Operating Lease, Right-of-Use Asset 380M USD -17.5%
Intangible Assets, Net (Excluding Goodwill) 9.81B USD +33.5%
Goodwill 6.49B USD -4.73%
Other Assets, Noncurrent 631M USD -16.3%
Assets 28.3B USD +0.43%
Accounts Payable, Current 423M USD -3.95%
Employee-related Liabilities, Current 289M USD +4.34%
Liabilities, Current 5.43B USD +8.02%
Accrued Income Taxes, Noncurrent 162M USD -58.9%
Deferred Income Tax Liabilities, Net 882M USD +21.2%
Operating Lease, Liability, Noncurrent 357M USD -16.7%
Other Liabilities, Noncurrent 744M USD -0.51%
Liabilities 12B USD -12.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -146M USD +8.54%
Retained Earnings (Accumulated Deficit) 19B USD +9.3%
Stockholders' Equity Attributable to Parent 14.8B USD +10.5%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 16.4B USD +13%
Liabilities and Equity 28.3B USD +0.43%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 553M USD +21.5%
Net Cash Provided by (Used in) Financing Activities -440M USD -913%
Net Cash Provided by (Used in) Investing Activities -66M USD +93.1%
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 169M shares +0.48%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.7B USD -25.7%
Deferred Tax Assets, Valuation Allowance 1.28B USD -36.2%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Operating Lease, Liability 490M USD +14%
Depreciation 277M USD +8.61%
Payments to Acquire Property, Plant, and Equipment 45.9M USD -31.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 1.63B USD +11.1%
Lessee, Operating Lease, Liability, to be Paid 592M USD +25.8%
Property, Plant and Equipment, Gross 5.71B USD +4.54%
Operating Lease, Liability, Current 90.3M USD -7.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 96.1M USD -10.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 106M USD -4.32%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure +27%
Deferred Income Tax Expense (Benefit) 39.9M USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 101M USD +153%
Lessee, Operating Lease, Liability, to be Paid, Year Three 83.5M USD +3.73%
Deferred Tax Assets, Operating Loss Carryforwards 1.7B USD -7.88%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 8M shares 0%
Unrecognized Tax Benefits 173M USD -71.4%
Lessee, Operating Lease, Liability, to be Paid, Year Four 86.1M USD +31.1%
Additional Paid in Capital 489M USD +102%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 148M USD +31.3%
Deferred Tax Assets, Net of Valuation Allowance 2.93B USD +13.3%
Share-based Payment Arrangement, Expense -281M USD +2.3%
Interest Expense 262M USD +13.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares